Table 2. Clinical characteristics summary statistics among 102 ENL patients initiating thalidomide by treatment compliance.
| Clinical Characteristics | Total | Treatment Compliance | |
|---|---|---|---|
| No | Yes | ||
| Number of Patients | 102 | 34 | 68 |
| Thalidomide indication, % | |||
| Steroid Dependency | 89.2 | 85.3 | 91.2 |
| Steroid Toxicity | 7.8 | 11.8 | 5.9 |
| Contraindication | 2.9 | 2.9 | 2.9 |
| Duration of Thalidomide use, months | |||
| mean (sd) | 9.4 (8.6) | 4.8 (3.6) | 11.7 (9.4) |
| ENL Presentation and Type, % | |||
| Classical | |||
| Acute | 12.8 | 14.7 | 11.7 |
| Recurrent | 25.5 | 20.6 | 27.9 |
| Chronic | 44.1 | 41.2 | 45.6 |
| Ulcerative | 17.6 | 23.5 | 14.7 |
| Duration of ENL, months | |||
| Mean (std) | 14.2 (11.0) | 14.6 (11.0) | 14.0 (11.1) |
| Median (25th, 75th) | 12 (5,24) | 12 (6,24) | 12 (4, 22) |
| MDT Status, % | |||
| Initial | 8.8 | 14.7 | 5.9 |
| Current | 58.8 | 58.8 | 58.8 |
| Completed | 32.4 | 26.5 | 35.3 |
| Comorbidities, % | |||
| No | 77.5 | ||
| Yes | 22.5 | ||
| Diabetes | 7.8 | ||
| Asthma | 5.9 | ||
| TB | 5.9 | ||
| Hypertension | 2.9 | ||